Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Acute myeloid leukemia
Menin inhibitors, FLT3 and IDH combinations, venetoclax backbones and what comes after.
Live from ClinicalTrials.gov, fetched 2026-11-11 15:19 UTC. Every row links to its source record.
Drug trials updated in the last 16 months
600
the 600 most recently updated are shown
For relapsed or refractory disease
28%
171 trial titles name relapsed, refractory or recurrent disease
Led by industry
23%
139 trials with a company as lead sponsor
62 of the 600 acute myeloid leukemia trials are Phase 3; 52 were stopped early
Drug trials in this cancer with a registry update in the last 16 months, by phase. Each bar is split by where the trial stands today.
Running or not yet startedCompletedStopped early (terminated, withdrawn or suspended)
A trial that spans two phases counts as the later one. Stopped early is the registry status, whatever the reason given. Source: ClinicalTrials.gov, fetched live.
Programs: each drug in each segment
A program is one drug in one segment of acute myeloid leukemia (biomarker, line of therapy, setting), so the same drug can be Phase 3 in one segment and Phase 1 in another. Segments are read from each trial's title and conditions by published rules; 233 of 600 trials name no segment and are listed as Untagged.
Segment:All1L1L · Relapsed or refractory2L+ · Relapsed or refractoryAdvanced or metastaticCD33CD33 · Relapsed or refractoryFLT3FLT3 · 1LFLT3 · 1L · Relapsed or refractoryFLT3 · MaintenanceFLT3 · Relapsed or refractoryIDH1IDH1 · 1LIDH1 · 1L · MaintenanceIDH1 · 1L · Relapsed or refractoryIDH1 · Advanced or metastaticIDH1 · MaintenanceIDH1 · Relapsed or refractoryIDH2IDH2 · 1LIDH2 · MaintenanceIDH2 · Relapsed or refractoryKMT2AKMT2A · 1L
Modality:AllAntibodyAntibody-drug conjugateBispecific antibodyCell therapyOther or not recognisedRadioligandSmall moleculeVaccine
| Drug | Segment | Modality | Highest phase | Trials |
|---|---|---|---|---|
| Venetoclax University of Washington | Untagged | Small molecule | Ph3 | NCT04797767, NCT06917911, NCT04817241, NCT05564390 +50 |
| Azacitidine National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph3 | NCT05564390, NCT05564390, NCT07645469, NCT07722767 +45 |
| Fludarabine National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph3 | NCT05436418, NCT06996119, NCT05564390, NCT07604233 +32 |
| Venetoclax National Cancer Institute (NCI) | 1L | Small molecule | Ph3 | NCT05554406, NCT07925190, NCT07437950, NCT07478991 +28 |
| Azacitidine National Cancer Institute (NCI) | 1L | Other or not recognised | Ph3 | NCT05554406, NCT07925190, NCT07478991, NCT06852222 +25 |
| Cytarabine M.D. Anderson Cancer Center | Untagged | Other or not recognised | Ph3 | NCT03589729, NCT04797767, NCT06917911, NCT04817241 +25 |
| Cytarabine National Cancer Institute (NCI) | 1L | Other or not recognised | Ph3 | NCT05554406, NCT03709758, NCT00651261, NCT03069352 +24 |
| Cyclophosphamide National Cancer Institute (NCI) | Untagged | Small molecule | Ph3 | NCT05436418, NCT06996119, NCT06904066, NCT06013423 +23 |
| Venetoclax Second Affiliated Hospital of Nanchang University | Relapsed or refractory | Small molecule | Ph3 | NCT07926607, NCT05183035, NCT06651229, NCT03955783 +23 |
| Tacrolimus City of Hope Medical Center | Untagged | Other or not recognised | Ph3 | NCT06996119, NCT01885689, NCT06287944, NCT04262843 +18 |
| Fludarabine PedAL BCU, LLC | Relapsed or refractory | Other or not recognised | Ph3 | NCT05183035, NCT06834282, NCT04898894, NCT05457010 +14 |
| Busulfan City of Hope Medical Center | Untagged | Other or not recognised | Ph2/Ph3 | NCT06996119, NCT05564390, NCT03970096, NCT05565105 +13 |
| Melphalan National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph3 | NCT05436418, NCT06996119, NCT01885689, NCT05564390 +13 |
| Cytarabine M.D. Anderson Cancer Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT03263572, NCT05183035, NCT06177067, NCT04898894 +12 |
| Azacitidine PedAL BCU, LLC | Relapsed or refractory | Other or not recognised | Ph3 | NCT05183035, NCT07770698, NCT06177067, NCT06454409 +10 |
| Thiotepa Fred Hutchinson Cancer Center | Untagged | Other or not recognised | Ph2/Ph3 | NCT06013423, NCT03970096, NCT06195891, NCT03779854 +10 |
| Mycophenolate Mofetil City of Hope Medical Center | Untagged | Other or not recognised | Ph3 | NCT06996119, NCT06013423, NCT04262843, NCT07634536 +9 |
| Venetoclax M.D. Anderson Cancer Center | 1L · Relapsed or refractory | Small molecule | Ph2/Ph3 | NCT03661307, NCT03214562, NCT04746235, NCT03629171 +7 |
| Azacitidine Beat AML, LLC | 1L · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT03013998, NCT03013998, NCT03013998, NCT03013998 +6 |
| Mycophenolate Mofetil Fred Hutchinson Cancer Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT04375631, NCT02861417, NCT05805605, NCT03128034 +6 |
| Cladribine M.D. Anderson Cancer Center | Untagged | Other or not recognised | Ph2/Ph3 | NCT03589729, NCT04797767, NCT02250937, NCT06232655 +5 |
| Daunorubicin National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph2/Ph3 | NCT04817241, NCT05564390, NCT07228273, NCT07255872 +5 |
| Idarubicin M.D. Anderson Cancer Center | Untagged | Other or not recognised | Ph3 | NCT03589729, NCT07604233, NCT07228273, NCT07228273 +5 |
| Daunorubicin Dana-Farber Cancer Institute | 1L | Other or not recognised | Ph3 | NCT03709758, NCT00651261, NCT07078591, NCT05939180 +4 |
| Daunorubicin Hydrochloride National Cancer Institute (NCI) | 1L | Other or not recognised | Ph3 | NCT05554406, NCT02835222, NCT02521493, NCT02971397 +4 |
| Fludarabine Phosphate Roswell Park Cancer Institute | Relapsed or refractory | Other or not recognised | Ph3 | NCT06871410, NCT07582172, NCT05092451, NCT02861417 +4 |
| Cytarabine M.D. Anderson Cancer Center | 1L · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT03214562, NCT03013998, NCT03013998, NCT03013998 +3 |
| fludarabine phosphate National Cancer Institute (NCI) | Untagged | Other or not recognised | Ph2/Ph3 | NCT06904066, NCT06013423, NCT04262843, NCT02250937 +3 |
| Methotrexate Fred Hutchinson Cancer Center | Untagged | Other or not recognised | Ph3 | NCT03970096, NCT06128070, NCT03121014, NCT03779854 +3 |
| Cyclosporine Fred Hutchinson Cancer Center | Untagged | Other or not recognised | Ph2/Ph3 | NCT06013423, NCT03970096, NCT02416388, NCT03434730 +2 |
| Gemtuzumab Ozogamicin M.D. Anderson Cancer Center | Untagged | Antibody-drug conjugate | Ph3 | NCT03589729, NCT06917911, NCT05564390, NCT05955261 +2 |
| Venetoclax Institute of Hematology & Blood Diseases Hospital, China | Maintenance | Small molecule | Ph3 | NCT07539818, NCT06954987, NCT05010772, NCT06129734 +2 |
| Cyclosporine Fred Hutchinson Cancer Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT04375631, NCT03128034, NCT04195633, NCT03246906 +1 |
| Decitabine M.D. Anderson Cancer Center | 1L · Relapsed or refractory | Other or not recognised | Ph2/Ph3 | NCT03661307, NCT03013998, NCT03013998, NCT03013998 +1 |
| Idarubicin M.D. Anderson Cancer Center | 1L | Other or not recognised | Ph3 | NCT00801489, NCT06034470, NCT07046078, NCT02688140 +1 |
| Azacitidine Institute of Hematology & Blood Diseases Hospital, China | Maintenance | Other or not recognised | Ph3 | NCT07539818, NCT07548983, NCT06498973, NCT03613532 |
| Gemtuzumab Ozogamicin PedAL BCU, LLC | Relapsed or refractory | Antibody-drug conjugate | Ph3 | NCT05183035, NCT03672539, NCT03374332, NCT04915612 |
| Granulocyte Colony-Stimulating Factor City of Hope Medical Center | Untagged | Other or not recognised | Ph3 | NCT06059391, NCT04262843, NCT06158828, NCT07735117 |
| Azacitidine UNC Lineberger Comprehensive Cancer Center | KMT2A · 1L | Other or not recognised | Ph3 | NCT07605949, NCT00658814, NCT07007312 |
| Azacitidine National Cancer Institute (NCI) | FLT3 | Other or not recognised | Ph3 | NCT06317649, NCT07862517, NCT02752035 |
| Azacitidine M.D. Anderson Cancer Center | FLT3 · Relapsed or refractory | Other or not recognised | Ph3 | NCT01892371, NCT04140487, NCT05586074 |
| Entospletinib Beat AML, LLC | 1L · Relapsed or refractory | Small molecule | Ph2/Ph3 | NCT03013998, NCT03013998, NCT03013998 |
| Etoposide Children's Oncology Group | 1L | Other or not recognised | Ph3 | NCT02521493, NCT01371981, NCT03164057 |
| G-CSF Washington University School of Medicine | Untagged | Other or not recognised | Ph3 | NCT02782546, NCT03849651, NCT03480360 |
| Gilteritinib National Cancer Institute (NCI) | FLT3 | Small molecule | Ph3 | NCT06317649, NCT03836209, NCT02752035 |
| Gilteritinib M.D. Anderson Cancer Center | FLT3 · Relapsed or refractory | Small molecule | Ph3 | NCT06235801, NCT04140487, NCT03182244 |
| Gilteritinib Beat AML, LLC | 1L · Relapsed or refractory | Small molecule | Ph2/Ph3 | NCT03013998, NCT03013998, NCT02115295 |
| Ivosidenib Ruijin Hospital | 1L | Small molecule | Ph3 | NCT07548710, NCT05401097, NCT05907057 |
| Mitoxantrone University of Washington | Untagged | Other or not recognised | Ph3 | NCT04797767, NCT04195945, NCT02724163 |
| Pevonedistat Takeda | Untagged | Small molecule | Ph3 | NCT04266795, NCT04090736, NCT03330821 |
| Quizartinib PETHEMA Foundation | 1L | Small molecule | Ph3 | NCT07478991, NCT04687761, NCT04687761 |
| Sirolimus City of Hope Medical Center | Relapsed or refractory | Other or not recognised | Ph3 | NCT07582172, NCT03246906, NCT01231412 |
| AG-120 Institut de Recherches Internationales Servier | IDH1 · 1L | Other or not recognised | Ph3 | NCT03173248, NCT02632708 |
| Arsenic trioxide Technische Universität Dresden | 1L | Other or not recognised | Ph3 | NCT02688140, NCT01409161 |
| Asparaginase Children's Oncology Group | 1L | Other or not recognised | Ph3 | NCT02521493, NCT01371981 |
| ASTX030 Taiho Oncology, Inc. | Untagged | Other or not recognised | Ph2/Ph3 | NCT04256317, NCT04256317 |
| Cytarabine M.D. Anderson Cancer Center | FLT3 · Relapsed or refractory | Other or not recognised | Ph3 | NCT01892371, NCT03182244 |
| Cytarabine Kura Oncology, Inc. | KMT2A · 1L | Other or not recognised | Ph3 | NCT07007312, NCT05886049 |
| Cytarabine Children's Oncology Group | FLT3 · 1L | Other or not recognised | Ph3 | NCT04293562, NCT03591510 |
| Daunorubicin Kura Oncology, Inc. | KMT2A · 1L | Other or not recognised | Ph3 | NCT07007312, NCT05886049 |
Showing the 60 most advanced of 886 programs.
Assets over time
600 trials updated in the last 16 months. Each row is an asset; each dot is one of its trials at first posting, sized by phase. Orange is Phase 3.
| Asset | Lead sponsor | |
|---|---|---|
| Azacitidine | National Cancer Institute (NCI) | |
| Cytarabine | Uma Borate | |
| Venetoclax | University of Ulm | |
| Cyclophosphamide | Fred Hutchinson Cancer Center | |
| Busulfan | City of Hope Medical Center | |
| Revumenib | Syndax Pharmaceuticals | |
| Ziftomenib | Kura Oncology, Inc. | |
| Fludarabine | PedAL BCU, LLC | |
| Gilteritinib | M.D. Anderson Cancer Center | |
| Ivosidenib | Memorial Sloan Kettering Cancer Center | |
| AG-120 | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| Gemtuzumab Ozogamicin | University of Washington | |
| Bleximenib | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| Lisaftoclax | Guangdong Second Provincial General Hospital | |
| Arsenic Trioxide | University of Michigan Rogel Cancer Center | |
| Cyclosporine | Fred Hutchinson Cancer Center | |
| Pivekimab Sunirine | AbbVie | |
| Vyxeos | Shaare Zedek Medical Center | |
| BL-M11D1 | SystImmune Inc. | |
| Pevonedistat | Takeda | |
| Venetoclax Oral Tablet | Technische Universität Dresden | |
| Asparaginase | Children's Oncology Group | |
| Lisaftoclax+daunorubicin+cytarabine | First Affiliated Hospital of Zhejiang University | |
| Mesutoclax | Beijing InnoCare Pharma Tech Co., Ltd. | |
| QTX-2101 + ATRA | Quetzal Therapeutics | |
| mocravimod | Priothera SAS | |
| High intensity therapies | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | |
| Daunorubicin/Idarubicin | Institute of Hematology & Blood Diseases Hospital, China | |
| Asparaginase Erwinia chrysanthemi | Children's Oncology Group | |
| IPN60340 + azacitidine + venetoclax | Ipsen |
All trials
Site countries come from each record's listed locations. Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered.
| Trial | Phase | Sponsor | Status | Posted | Primary completion |
|---|---|---|---|---|---|
| NCT07925190 A Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients Single-country: China (1 site) Decision brief → | Ph3 | Beijing InnoCare Pharma Tech Co., Ltd. | not yet recruiting | 2026-11-09 | 2029-12 |
| NCT07761702 Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML No sites listed Decision brief → | Ph3 | Shanghai Jiao Tong University School of Medicine | not yet recruiting | 2026-08-12 | 2029-10-01 |
| NCT07735117 Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML No sites listed Decision brief → | Ph3 | Ruijin Hospital | not yet recruiting | 2026-07-29 | 2028-07-20 |
| NCT07712848 DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML Single-country: China (1 site) Decision brief → | Ph3 | The Second Affiliated Hospital of Kunming Medical University | recruiting | 2026-07-20 | 2026-12-01 |
| NCT07686965 Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse No sites listed Decision brief → | Ph3 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2026-07-07 | 2030-08-10 |
| NCT07651163 Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Single-country: China (1 site) Decision brief → | Ph2/Ph3 | First Affiliated Hospital of Zhejiang University | enrolling by invitation | 2026-06-16 | 2029-12 |
| NCT07651176 Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy Single-country: China (1 site) Decision brief → | Ph2/Ph3 | First Affiliated Hospital of Zhejiang University | enrolling by invitation | 2026-06-16 | 2029-12 |
| EVICTION 3 · NCT07623187 A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy No sites listed Decision brief → | Ph2/Ph3 | Ipsen | not yet recruiting | 2026-06-03 | 2031-05-31 |
| NCT07597941 Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients No sites listed Decision brief → | Ph2/Ph3 | The Affiliated People's Hospital of Ningbo University | not yet recruiting | 2026-05-20 | 2028-06 |
| NCT07583888 VABu Conditioning in Elderly AML HSCT Single-country: China (1 site) Decision brief → | Ph2/Ph3 | The First Affiliated Hospital of Soochow University | recruiting | 2026-05-13 | 2027-08-15 |
| REVIVAL · NCT07581002 A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) 7 countries, 16% of sites in the US Decision brief → | Ph2/Ph3 | AbbVie | recruiting | 2026-05-12 | 2032-06 |
| NCT07539818 Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML Single-country: China (1 site) Decision brief → | Ph3 | Institute of Hematology & Blood Diseases Hospital, China | recruiting | 2026-04-20 | 2030-04-01 |
| NCT07514936 Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia Single-country: China (1 site) Decision brief → | Ph3 | Chinese PLA General Hospital | recruiting | 2026-04-07 | 2027-09-30 |
| QUATRO-APL · NCT07504458 Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia 5 countries, 50% of sites in the US Decision brief → | Ph3 | Quetzal Therapeutics | recruiting | 2026-03-31 | 2027-03 |
| VENP-A-QUI · NCT07478991 Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) Single-country: Spain (52 sites) Decision brief → | Ph3 | PETHEMA Foundation | recruiting | 2026-03-18 | 2030-04 |
| NCT07255872 A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia Single-country: China (1 site) Decision brief → | Ph2/Ph3 | Sichuan Baili Pharmaceutical Co., Ltd. | recruiting | 2025-12-01 | 2027-12 |
| NCT07223814 Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML) 13 countries, 12% of sites in the US Decision brief → | Ph3 | Stichting Hemato-Oncologie voor Volwassenen Nederland | recruiting | 2025-11-03 | 2030-06 |
| REVEAL-ND NPM1 · NCT07211958 Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation 23 countries, 6% of sites in the US Decision brief → | Ph3 | Syndax Pharmaceuticals | recruiting | 2025-10-08 | 2029-06 |
| NCT07132684 Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients Single-country: China (1 site) Decision brief → | Ph3 | Institute of Hematology & Blood Diseases Hospital, China | recruiting | 2025-08-20 | 2027-08-30 |
| NCT07022678 Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia Single-country: United States (39 sites) Decision brief → | Ph3 | Children's Oncology Group | recruiting | 2025-06-15 | 2032-01-15 |
| NCT07007312 Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML 17 countries, 32% of sites in the US Decision brief → | Ph3 | Kura Oncology, Inc. | recruiting | 2025-06-05 | 2031-11 |
| cAMeLot-2 · NCT06852222 A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) 26 countries, 23% of sites in the US Decision brief → | Ph3 | Janssen Research & Development, LLC | recruiting | 2025-02-28 | 2029-06-22 |
| NCT06788756 L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML 9 countries, 29% of sites in the US Decision brief → | Ph2/Ph3 | Moleculin Biotech, Inc. | recruiting | 2025-01-23 | 2029-08 |
| NCT06744504 Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 Single-country: China (1 site) Decision brief → | Ph3 | Institute of Hematology & Blood Diseases Hospital, China | recruiting | 2024-12-20 | 2027-12-01 |
| IMPACT-AML · NCT06713837 IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. 8 countries, 0% of sites in the US Decision brief → | Ph3 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | recruiting | 2024-12-03 | 2028-01 |
| NCT06652438 Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML 18 countries, 7% of sites in the US Decision brief → | Ph3 | Stichting Hemato-Oncologie voor Volwassenen Nederland | recruiting | 2024-10-22 | 2029-12-13 |
| QuANTUM-WILD · NCT06578247 Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML 28 countries, 18% of sites in the US Decision brief → | Ph3 | Daiichi Sankyo | active not recruiting | 2024-08-29 | 2030-06-26 |
| OPTISAGE · NCT06083129 Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor Single-country: France (28 sites) Decision brief → | Ph3 | Assistance Publique - Hôpitaux de Paris | recruiting | 2023-10-13 | 2028-11-28 |
| NCT06073730 Comparison of the Efficacy and Safety of Venetoclax in Combination With 3 Days Decitabine (DEC3-VEN) vs. Venetoclax in Combination With Azacitidine (VIALE-A) in the Treatment of Elderly Patients or Unfit, New-diagnosis Acute Myeloid Leukemia Patients Single-country: China (1 site) Decision brief → | Ph3 | The Second Affiliated Hospital of Kunming Medical University | completed | 2023-10-10 | 2025-12-30 |
| NCT05939180 VA vs DA for Newly Diagnosed Hig-risk AML Single-country: China (2 sites) Decision brief → | Ph2/Ph3 | The First Affiliated Hospital of Soochow University | recruiting | 2023-07-11 | 2026-06-13 |
| NCT05907057 An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. 4 countries, 0% of sites in the US Decision brief → | Ph3 | Servier Affaires Médicales | recruiting | 2023-06-18 | 2027-10-15 |
| NCT05654194 Azacitidine Combined With Venetoclax and ATRA in Newly Diagnosed AML Single-country: China (1 site) Decision brief → | Ph3 | The First Affiliated Hospital of Soochow University | completed | 2022-12-16 | 2024-09-29 |
| NCT05586074 HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML Single-country: China (1 site) Decision brief → | Ph3 | Sunshine Lake Pharma Co., Ltd. | recruiting | 2022-10-19 | 2027-11-30 |
| NCT05457556 Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome 3 countries, 90% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | active not recruiting | 2022-07-14 | 2026-06-30 |
| MO-TRANS · NCT05429632 Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT 14 countries, 19% of sites in the US Decision brief → | Ph3 | Priothera SAS | recruiting | 2022-06-23 | 2027-05 |
| NCT05183035 Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) 20 countries, 50% of sites in the US Decision brief → | Ph3 | PedAL BCU, LLC | active not recruiting | 2022-01-10 | 2027-02 |
| NCT04708054 Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS Single-country: United States (1 site) Decision brief → | Ph2/Ph3 | M.D. Anderson Cancer Center | recruiting | 2021-01-13 | 2027-12-31 |
| NCT04628026 Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 8 countries, 0% of sites in the US Decision brief → | Ph3 | University of Ulm | recruiting | 2020-11-13 | 2029-03 |
| NCT04293562 A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations 4 countries, 90% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | recruiting | 2020-03-03 | 2029-06-30 |
| NCT04256317 A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) 10 countries, 33% of sites in the US Decision brief → | Ph2/Ph3 | Taiho Oncology, Inc. | recruiting | 2020-02-05 | 2027-11-01 |
| COSI · NCT04217278 A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT Single-country: United Kingdom (14 sites) Decision brief → | Ph2/Ph3 | University of Birmingham | active not recruiting | 2020-01-03 | 2026-05 |
| AMADEUS · NCT04173533 Randomised Study of Oral Azacitidine vs Placebo Maintenance in AML or MDS Patients After Allo-SCT Single-country: United Kingdom (20 sites) Decision brief → | Ph3 | University of Birmingham | completed | 2019-11-22 | 2026-04-29 |
| VIALE-T · NCT04161885 A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) 18 countries, 26% of sites in the US Decision brief → | Ph3 | AbbVie | terminated | 2019-11-13 | 2025-09-23 |
| PEVOLAM · NCT04090736 Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy Single-country: Spain (62 sites) Decision brief → | Ph3 | PETHEMA Foundation | active not recruiting | 2019-09-16 | 2023-06-30 |
| NCT03844048 An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial 23 countries, 13% of sites in the US Decision brief → | Ph3 | AbbVie | active not recruiting | 2019-02-18 | 2027-08 |
| HOVON150AML · NCT03839771 A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy 15 countries, 0% of sites in the US Decision brief → | Ph3 | Stichting Hemato-Oncologie voor Volwassenen Nederland | active not recruiting | 2019-02-15 | 2027-04-17 |
| NCT03480360 Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Single-country: United States (1 site) Decision brief → | Ph3 | Dartmouth-Hitchcock Medical Center | completed | 2018-03-29 | 2025-02-14 |
| NCT03182244 A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation 5 countries, 0% of sites in the US Decision brief → | Ph3 | Astellas Pharma Inc | completed | 2017-06-09 | 2023-12-25 |
| AGILE · NCT03173248 Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation 20 countries, 2% of sites in the US Decision brief → | Ph3 | Institut de Recherches Internationales Servier | active not recruiting | 2017-06-01 | 2021-03-18 |
| NCT03069352 A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy 24 countries, 6% of sites in the US Decision brief → | Ph3 | AbbVie | completed | 2017-03-03 | 2019-02-15 |
| NCT03013998 Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Single-country: United States (31 sites) Decision brief → | Ph2/Ph3 | Beat AML, LLC | recruiting | 2017-01-09 | 2032-12 |
| Viale-a · NCT02993523 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy 29 countries, 14% of sites in the US Decision brief → | Ph3 | AbbVie | active not recruiting | 2016-12-15 | 2021-12-01 |
| NCT02752035 A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy 13 countries, 11% of sites in the US Decision brief → | Ph3 | Astellas Pharma Global Development, Inc. | completed | 2016-04-26 | 2023-03-10 |
| Myechild01 · NCT02724163 International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia 6 countries, 0% of sites in the US Decision brief → | Ph3 | University of Birmingham | active not recruiting | 2016-03-31 | 2031-12 |
| TUD-APOLLO-064 · NCT02688140 Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia 5 countries, 0% of sites in the US Decision brief → | Ph3 | Technische Universität Dresden | completed | 2016-02-23 | 2025-01-20 |
| NCT02521493 Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome 6 countries, 88% of sites in the US Decision brief → | Ph3 | Children's Oncology Group | active not recruiting | 2015-08-13 | 2024-06-30 |
| BIG-1 · NCT02416388 Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR Single-country: France (56 sites) Decision brief → | Ph2/Ph3 | University Hospital, Angers | recruiting | 2015-04-15 | 2025-07-30 |
| NCT01371981 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia 5 countries, 89% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | completed | 2011-06-13 | 2019-03-31 |
| NCT01231412 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant 3 countries, 55% of sites in the US Decision brief → | Ph3 | Fred Hutchinson Cancer Center | completed | 2010-11-01 | 2016-10-08 |
| NCT00651261 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia 2 countries, 97% of sites in the US Decision brief → | Ph3 | Alliance for Clinical Trials in Oncology | completed | 2008-04-02 | 2016-07 |
| NCT00093470 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission 3 countries, 99% of sites in the US Decision brief → | Ph3 | National Cancer Institute (NCI) | completed | 2004-10-08 | 2015-02-20 |
| NCT00085124 Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia Single-country: United States (2 sites) Decision brief → | Ph3 | National Cancer Institute (NCI) | completed | 2004-06-11 | 2007-06 |
| NCT07925554 Interferon-α Maintenance in Favorable-Risk AML Single-country: China (1 site) Decision brief → | Ph2 | Peking University People's Hospital | recruiting | 2026-11-09 | 2027-10-31 |
| NCT07926607 Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Second Affiliated Hospital of Nanchang University | not yet recruiting | 2026-11-09 | 2029-12-31 |
| Dual CARCIK · NCT07877610 CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults Single-country: Italy (2 sites) Decision brief → | Ph1/Ph2 | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | recruiting | 2026-10-16 | 2028-10 |
| NCT07874737 Mitoxantrone Hydrochloride Liposome Combined With Cladribine And Sotorasib For Relapsed Refractory Acute Myeloid Leukemia No sites listed Decision brief → | Ph2 | The Affiliated People's Hospital of Ningbo University | not yet recruiting | 2026-10-15 | 2028-12 |
| NCT07873827 KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies No sites listed Decision brief → | Ph1/Ph2 | Stemline Therapeutics, Inc. | not yet recruiting | 2026-10-14 | 2028-05-12 |
| NCT07867626 Phase II De-Escalation Study of Metronomic Decitabine/Cedazuridine Plus Venetoclax in AML Single-country: United States (1 site) Decision brief → | Ph2 | Rutgers, The State University of New Jersey | not yet recruiting | 2026-10-09 | 2028-06 |
| NCT07862517 Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) No sites listed Decision brief → | Ph2 | National Cancer Institute (NCI) | not yet recruiting | 2026-10-07 | 2027-12-31 |
| NCT07819396 Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Single-country: United States (1 site) Decision brief → | Ph2 | Fred Hutchinson Cancer Center | not yet recruiting | 2026-09-14 | 2031-06-01 |
| HLA-AML · NCT07813390 Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure Single-country: China (1 site) Decision brief → | Ph2 | Guangdong Second Provincial General Hospital | enrolling by invitation | 2026-09-10 | 2027-09-01 |
| NCT07783100 Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Single-country: China (1 site) Decision brief → | Ph2 | The First Affiliated Hospital of Xiamen University | recruiting | 2026-08-24 | 2028-03-31 |
| TP53 · NCT07779031 A Single-Arm, Open Phase I Clinical Study of Selinexor in Combination With Azacitidine for the Treatment of High-Risk AML/MDS Patients After Allo-HSCT Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Liping Dou | active not recruiting | 2026-08-21 | 2028-04-30 |
| NCT07770698 A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia No sites listed Decision brief → | Ph1/Ph2 | BeOne Medicines | not yet recruiting | 2026-08-18 | 2030-04-30 |
| FLAsH-IV-AML · NCT07766850 Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia Single-country: Sweden (1 site) Decision brief → | Ph1/Ph2 | Christer C Nilsson | not yet recruiting | 2026-08-17 | 2029-06 |
| NCT07761533 PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Chaser Therapeutics, Inc. | recruiting | 2026-08-12 | 2027-09 |
| NCT07757672 Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML. No sites listed Decision brief → | Ph1/Ph2 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2026-08-11 | 2029-04-30 |
| GAVE001 · NCT07755202 Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia Single-country: Canada (1 site) Decision brief → | Ph2 | Florian Kuchenbauer | not yet recruiting | 2026-08-10 | 2029-10-01 |
| NCT07754799 A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia No sites listed Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | not yet recruiting | 2026-08-10 | 2029-09-30 |
| NCT07749976 GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors No sites listed Decision brief → | Ph1/Ph2 | Vitruviae | not yet recruiting | 2026-08-06 | 2028-01 |
| VENTURE-AML · NCT07748455 HMA-Venetoclax Induction in Newly Diagnosed AML Single-country: Pakistan (1 site) Decision brief → | Ph2 | Pakistan Blood and Marrow Transplant (PBMT) Group | not yet recruiting | 2026-08-05 | 2027-12-31 |
| NCT07743112 A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia Single-country: China (1 site) Decision brief → | Ph2 | Maxinovel Pty., Ltd. | recruiting | 2026-08-03 | 2027-09-01 |
| ALIGN-AML · NCT07735208 Geriatric Assessment-Guided Treatment Selection in Older Adults With Acute Myeloid Leukemia Single-country: United States (1 site) Decision brief → | Ph2 | University of Rochester | not yet recruiting | 2026-07-29 | 2031-11-30 |
| MIDOVEN · NCT07726576 Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia Single-country: France (3 sites) Decision brief → | Ph1/Ph2 | University Hospital, Bordeaux | not yet recruiting | 2026-07-24 | 2027-09 |
| NCT07722312 S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation No sites listed Decision brief → | Ph1/Ph2 | Servier | not yet recruiting | 2026-07-23 | 2029-08-11 |
| NCT07719348 A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies No sites listed Decision brief → | Ph1/Ph2 | Servier | not yet recruiting | 2026-07-22 | 2027-11-01 |
| NCT07710534 Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN Single-country: United States (1 site) Decision brief → | Ph2 | Virginia Commonwealth University | recruiting | 2026-07-17 | 2031-09-30 |
| NCT07686107 Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML." No sites listed Decision brief → | Ph2 | Therapeutic Advances in Childhood Leukemia Consortium | not yet recruiting | 2026-07-07 | 2029-12-31 |
| NCT07672262 VA Consolidation in Intermediate-Risk AML Single-country: China (1 site) Decision brief → | Ph2 | The First Affiliated Hospital of Soochow University | recruiting | 2026-06-26 | 2030-06-01 |
| NCT07664839 Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations Single-country: China (1 site) Decision brief → | Ph2 | Shen yang | not yet recruiting | 2026-06-24 | 2028-05-31 |
| NCT07663864 Luspatercept for CIA in AML Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Guangdong Second Provincial General Hospital | recruiting | 2026-06-23 | 2026-12-31 |
| NCT07651475 Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Single-country: China (1 site) Decision brief → | Ph2 | Liping Dou | active not recruiting | 2026-06-16 | 2027-03-31 |
| NCT07643636 Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML No sites listed Decision brief → | Ph2 | Dongguan People's Hospital | not yet recruiting | 2026-06-11 | 2028-06-01 |
| NCT07642453 VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. No sites listed Decision brief → | Ph2 | Hematology department of the 920th hospital | not yet recruiting | 2026-06-11 | 2028-06-01 |
| NCT07634536 Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant Single-country: United States (1 site) Decision brief → | Ph2 | Stanford University | not yet recruiting | 2026-06-09 | 2028-08 |
| NCT07623616 A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia Single-country: Japan (20 sites) Decision brief → | Ph2 | Kyowa Kirin Co., Ltd. | recruiting | 2026-06-03 | 2027-03 |
| RAVEN · NCT07605949 Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML Single-country: United States (1 site) Decision brief → | Ph2 | UNC Lineberger Comprehensive Cancer Center | not yet recruiting | 2026-05-26 | 2028-07 |
| NCT07607418 Ivosidenib as Maintenance Therapy in Transplant-Ineligible IDH1-mutated AML and HR-MDS Single-country: China (1 site) Decision brief → | Ph2 | Ruijin Hospital | recruiting | 2026-05-26 | 2027-05-30 |
| NCT07604233 Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | not yet recruiting | 2026-05-22 | 2031-06-03 |
| NCT07604064 A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia Single-country: Japan (1 site) Decision brief → | Ph2 | Kissei Pharmaceutical Co., Ltd. | recruiting | 2026-05-22 | 2030-09 |
| FT-RIC-HAPLO · NCT07598110 FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML No sites listed Decision brief → | Ph2 | Institut Paoli-Calmettes | not yet recruiting | 2026-05-20 | 2030-10-10 |
| NCT07591649 Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Masonic Cancer Center, University of Minnesota | recruiting | 2026-05-18 | 2030-03-01 |
| CAR-p40-T · NCT07584889 Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies Single-country: China (1 site) Decision brief → | Ph1/Ph2 | Shenzhen University General Hospital | recruiting | 2026-05-13 | 2029-04-19 |
| NCT07582172 Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Single-country: United States (1 site) Decision brief → | Ph2 | City of Hope Medical Center | recruiting | 2026-05-12 | 2031-11-05 |
| NCT07575412 SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS Single-country: China (1 site) Decision brief → | Ph2 | The First Affiliated Hospital of Soochow University | not yet recruiting | 2026-05-08 | 2029-06 |
| PREeMPT · NCT07572929 A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant Single-country: United States (1 site) Decision brief → | Ph2 | Medical College of Wisconsin | not yet recruiting | 2026-05-07 | 2034-02-01 |
| NCT07566377 Cord Blood Transplantation in Children and Young Adults With Blood Cancer Single-country: United States (1 site) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2026-05-05 | 2030-04-28 |
| NCT07563010 Menin-Inhibitor Targeted Maintenance in AML No sites listed Decision brief → | Ph2 | Center for International Blood and Marrow Transplant Research | not yet recruiting | 2026-05-01 | 2031-06 |
| NCT07562568 SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS Single-country: China (1 site) Decision brief → | Ph2 | The First Affiliated Hospital of Soochow University | not yet recruiting | 2026-05-01 | 2030-06 |
| NCT07563179 Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia Single-country: China (1 site) Decision brief → | Ph2 | Shenzhen University General Hospital | recruiting | 2026-05-01 | 2029-06-30 |
| MATCH-Treg · NCT07552649 Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia Single-country: Italy (2 sites) Decision brief → | Ph2 | Antonio Pierini | not yet recruiting | 2026-04-27 | 2028-04 |
| NCT07548710 Study of SA+X in the Treatment of Newly Diagnosed AML Single-country: China (1 site) Decision brief → | Ph2 | Ruijin Hospital | recruiting | 2026-04-23 | 2027-05-31 |
| MYELO-CAN:ABX · NCT07528417 Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX) Single-country: Canada (1 site) Decision brief → | Ph2 | University of Manitoba | not yet recruiting | 2026-04-14 | 2028-04-30 |
| DECISIVO · NCT07507760 Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients 2 countries, 0% of sites in the US Decision brief → | Ph2 | PETHEMA Foundation | recruiting | 2026-04-02 | 2029-04 |
| NCT07471841 Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax Single-country: United States (1 site) Decision brief → | Ph2 | Timothy Pardee | recruiting | 2026-03-13 | 2028-06 |
| NCT07437950 Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) 2 countries, 97% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | recruiting | 2026-02-27 | 2034-09-22 |
| NCT07425782 Venetoclax Combined With Azacitidine for Consolidation Therapy in AML Single-country: China (1 site) Decision brief → | Ph2 | The First Affiliated Hospital of Soochow University | recruiting | 2026-02-23 | 2028-11-26 |
| NCT07423104 A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia No sites listed Decision brief → | Ph2 | University of Rochester | not yet recruiting | 2026-02-20 | 2029-02-01 |
| NCT07392242 A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia Single-country: United States (7 sites) Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2026-02-06 | 2028-01 |
| NCT07392970 Motixafortide for MRD Sensitization in AML Single-country: United States (1 site) Decision brief → | Ph2 | Washington University School of Medicine | recruiting | 2026-02-06 | 2028-08-02 |
| NCT07356154 A Study of Revumenib and Mezigdomide in People With Leukemia Single-country: United States (10 sites) Decision brief → | Ph1/Ph2 | Memorial Sloan Kettering Cancer Center | recruiting | 2026-01-21 | 2029-01-16 |
| NCT07304011 Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent Single-country: United States (2 sites) Decision brief → | Ph2 | University of California, Davis | recruiting | 2025-12-26 | 2027-12-01 |
| NCT07228273 Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia Single-country: United States (1 site) Decision brief → | Ph2 | OHSU Knight Cancer Institute | recruiting | 2025-11-14 | 2029-06-24 |
| NCT07216443 Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Single-country: United States (6 sites) Decision brief → | Ph2 | Orca Biosystems, Inc. | recruiting | 2025-10-14 | 2027-11 |
| NCT07163793 Pilot Study of Reduced Venetoclax Exposure Single-country: United States (1 site) Decision brief → | Ph2 | Northwell Health | active not recruiting | 2025-09-09 | 2026-10 |
| MOMENTUM · NCT07155226 Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression 9 countries, 20% of sites in the US Decision brief → | Ph1/Ph2 | AstraZeneca | recruiting | 2025-09-04 | 2029-02-15 |
| NCT07153497 Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy) No sites listed Decision brief → | Ph2 | National Cancer Institute (NCI) | not yet recruiting | 2025-09-04 | 2030-04-26 |
| NCT07078591 Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML Single-country: China (1 site) Decision brief → | Ph2 | Beijing 302 Hospital | recruiting | 2025-07-22 | 2030-06 |
| NCT07060001 Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker Single-country: United States (1 site) Decision brief → | Ph2 | The Methodist Hospital Research Institute | recruiting | 2025-07-11 | 2028-12 |
| NCT07053020 A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | M.D. Anderson Cancer Center | not yet recruiting | 2025-07-08 | 2028-06-30 |
| NCT07046078 Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer Single-country: United States (1 site) Decision brief → | Ph2 | Fred Hutchinson Cancer Center | recruiting | 2025-07-01 | 2027-06-30 |
| RELEVANT · NCT07025824 Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation Single-country: Germany (17 sites) Decision brief → | Ph2 | Technische Universität Dresden | recruiting | 2025-06-18 | 2029-09 |
| NCT07008638 Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML) Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Masonic Cancer Center, University of Minnesota | recruiting | 2025-06-06 | 2027-12-30 |
| ROVER-01 · NCT06987058 RVU120 Rollover Study 2 countries, 0% of sites in the US Decision brief → | Ph2 | Ryvu Therapeutics SA | enrolling by invitation | 2025-05-23 | 2026-12 |
| NCT06969430 A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) Single-country: United States (7 sites) Decision brief → | Ph1/Ph2 | Debiopharm International SA | recruiting | 2025-05-13 | 2031-11 |
| NCT06954987 Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) No sites listed Decision brief → | Ph2 | National Cancer Institute (NCI) | not yet recruiting | 2025-05-02 | 2028-05-15 |
| NCT06930352 Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy Single-country: United States (1 site) Decision brief → | Ph2 | Uma Borate | recruiting | 2025-04-16 | 2028-01-31 |
| NCT06928662 Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Single-country: United States (1 site) Decision brief → | Ph1/Ph2 | Fred Hutchinson Cancer Center | recruiting | 2025-04-15 | 2028-03-09 |
| NCT06928376 A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients Single-country: China (1 site) Decision brief → | Ph2 | Chinese PLA General Hospital | recruiting | 2025-04-15 | 2025-09-01 |
| NCT06917911 Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) 2 countries, 98% of sites in the US Decision brief → | Ph2 | National Cancer Institute (NCI) | recruiting | 2025-04-09 | 2027-11-25 |
| NCT06904482 Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood Single-country: United States (1 site) Decision brief → | Ph2 | Case Comprehensive Cancer Center | recruiting | 2025-04-01 | 2027-02-24 |
| NCT06903702 A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia No sites listed Decision brief → | Ph2 | Memorial Sloan Kettering Cancer Center | withdrawn | 2025-04-01 | 2027-06 |
| NCT06824168 Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission 5 countries, 23% of sites in the US Decision brief → | Ph2 | Daiichi Sankyo | recruiting | 2025-02-13 | 2028-06-06 |
| NCT06816134 Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia Single-country: China (1 site) Decision brief → | Ph2 | The First Affiliated Hospital of Soochow University | recruiting | 2025-02-10 | 2028-01-30 |
| NCT06815003 Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning Single-country: United States (1 site) Decision brief → | Ph2 | City of Hope Medical Center | recruiting | 2025-02-07 | 2028-10-15 |
| NCT06811233 Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study Single-country: United States (1 site) Decision brief → | Ph2 | M.D. Anderson Cancer Center | recruiting | 2025-02-06 | 2029-08-31 |
| BMT-13 · NCT06802315 Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS) Single-country: United States (1 site) Decision brief → | Ph2 | University of Illinois Chicago | recruiting | 2025-01-31 | 2030-03 |
| NCT06744556 HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML Single-country: China (1 site) Decision brief → | Ph2 | Institute of Hematology & Blood Diseases Hospital, China | active not recruiting | 2024-12-20 | 2027-12-01 |
| PIVOT · NCT06717958 Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation Single-country: Germany (17 sites) Decision brief → | Ph2 | Technische Universität Dresden | recruiting | 2024-12-05 | 2029-10-01 |
| NCT06707493 Ivosidenib as Post-HSCT Maintenance for AML Single-country: United States (7 sites) Decision brief → | Ph2 | Massachusetts General Hospital | recruiting | 2024-11-27 | 2028-01-01 |